Adipotide Dosage: No Established Protocol, Trial and Primate Doses
Adipotide dosage: no two sources agree on a human protocol. What the terminated human trial and the primate study actually used, and why that is not a dose to copy.
The short version
There is no common human dosing protocol for adipotide, because no two sources agree on one. Most consumer pages publish no dose. Two give an estimate that does not match the one human trial's design, and a third reprints the primate study's dose tiers as a human schedule. What is sourced is the primate dose-finding data, including the kidney-injury signal, and the design of the one human trial. That trial was terminated early with no dose or result published.
- No common protocol is stated here, because no two sources converge on one.
- The one human trial was terminated early and never published its doses.
- The primate study tested 0.10-0.75 mg/kg/day. Kidney injury worsened with dose above roughly 0.25 mg/kg/day.
- Reconstitution and injection-volume math belongs on a calculator. There is no established dose to enter.
No source I could verify gives a usable, agreed-on human dose for adipotide. This page explains why and states what the one human trial and the primate study used. It does not convert an animal dose into a human one. Background on the compound, its evidence and its legal status is on the main adipotide page.
Adipotide dosage: the common protocol
No two sources I checked agree on a usable human dose, so no protocol is stated here. That is a safety choice, not a gap in research. The card below explains why.
Common protocol
No consistent protocol in circulation. No two real sources converge on a usable flat per-injection protocol. The only human dosing attempt on record is a terminated, unpublished first-in-human trial that escalated a weight-based dose across cohorts and never released a figure - not a flat amount this page could restate. Consumer dosing pages mostly publish no dose at all; the two that do (peptides.org, peptides.wiki) both give 0.01 mg/kg/day but say themselves that figure comes from anecdotal reports, not established human safety data, and a third site instead reprints the primate dose-finding tiers (0.10-0.43 mg/kg) as if they were a human protocol. None of that is a convergent, sourced, flat-dose common practice this page can responsibly state - and the only controlled dosing data that exists, the primate study, found a dose-dependent kidney-injury signal that this record will not convert into a self-administration number.
What the human trial actually used
The one human trial was a dose-escalation safety study, not a source of a recommended dose. Participants were to be assigned to one of up to five cohorts of 3 people. Each cohort got subcutaneous injections once daily for 28 days, at a higher dose than the last, only once the previous cohort tolerated it.
That is standard Phase 1 design for finding a maximum tolerated dose, and even a completed trial would not give a dose to copy. This one was not completed. It was terminated early, at the investigator’s request, and no dose figures or results have been published anywhere I could verify and cite.
What the primate study actually used
This is the only controlled, published dosing data for adipotide, and it is in monkeys, not people. A dose-finding study in obese rhesus macaques tested four daily subcutaneous doses over a two-week-per-dose schedule: 0.10, 0.25, 0.43 and 0.75 mg per kilogram of body weight. It picked 0.43 mg/kg/day as the optimal therapeutic dose, balancing weight-loss effect against the kidney findings below Barnhart 2011 - Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112., in the references below.
A larger follow-up study gave that fixed 0.43 mg/kg/day dose daily for 28 consecutive days, followed by a 4-week recovery period, across rhesus macaques, baboons and cynomolgus macaques Barnhart 2011 - Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112., in the references below.
The kidney-injury dose-response
In the primate study, serum creatinine increases were dose-dependent, with a clear signal above roughly 0.25 mg/kg/day. At the highest dose tested, 0.75 mg/kg/day, tissue examination showed more pronounced kidney tubule degeneration and regeneration Barnhart 2011 - Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112., in the references below.
Most monkeys on the optimal 0.43 mg/kg dose kept normal creatinine levels, but the effect was present to some degree across the tested dose range. This is the clearest safety data on the page. It is a reason to distrust any flat number on a consumer site that does not say where it came from.
How to reconstitute adipotide
Converting a target amount into an injection volume is arithmetic based on the vial’s diluent volume and resulting concentration. It does not replace the fact that this page has no established dose to put into it. The dosage calculator does the volume math for whatever number you enter. It does not choose, recommend or validate that number.
Who should not use it, and the risks
No FDA-reviewed contraindication list exists, because FDA has never reviewed adipotide for any use. The one human trial enrolled only men with advanced prostate cancer and obesity, under close clinical monitoring that included regular bloodwork. That shows who a monitored study considered eligible. It is not a safety clearance for anyone else.
Every primate species tested showed a dose-dependent kidney-injury signal Barnhart 2011 - Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112., in the references below. These people should not use an unregulated vial of this compound:
- Anyone with existing kidney disease.
- Anyone pregnant or breastfeeding.
- Anyone without access to baseline and follow-up kidney-function bloodwork.
Nobody should self-direct an unapproved research chemical with a documented organ-injury signal around a current medical condition.
Related
- Adipotide: the primate study, kidney risk and legal status
- AOD-9604 dosage: no published human study either
- Dosage calculator
- Research peptides and the law
Where to buy Adipotide for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
2 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
Common questions
What is the usual adipotide dose?
There is no usual dose, because no two sources agree on one. Most consumer dosing pages publish nothing. The two that publish a figure both call it an estimate, not an established human number, and it does not match the human trial's design. A third source reprints the primate study's dose tiers as a human schedule, which extrapolates an animal dose directly onto a person.
What dose did the human trial use?
The design was dose escalation: up to five cohorts of 3 participants, each cohort getting a higher dose only if the previous one tolerated it. The trial was terminated early, at the investigator's request, before the design completed. No dose figures or results were published in any source I could verify and cite.
What doses were used in the primate study?
A dose-finding study in obese rhesus macaques tested four daily subcutaneous doses: 0.10, 0.25, 0.43 and 0.75 mg per kilogram of body weight. It picked 0.43 mg/kg/day as optimal, balancing weight-loss effect against kidney-safety findings. A larger follow-up gave 0.43 mg/kg/day daily for 28 days, then a 4-week recovery period, in rhesus macaques, baboons and cynomolgus macaques.
Can I use the primate dose to work out a human dose?
No, and this page will not do that math. Scaling a primate dose to a human by body weight alone ignores real differences in metabolism and drug clearance. No source I could verify validated it for adipotide, and it would produce a precise-looking number with no backing. One source I checked did exactly that, reprinting the animal tiers as a human protocol.
Why does the kidney-injury dose matter if there is no human protocol?
It is the clearest safety signal that exists for this compound, from the only controlled dosing study ever run. Serum creatinine rose in a dose-dependent way above roughly 0.25 mg/kg/day, with more pronounced kidney tissue changes at the highest dose tested (0.75 mg/kg/day). Anyone using an unlabelled vial with no monitoring cannot know where their dose falls relative to that signal.
How do I work out reconstitution and injection volume?
That is arithmetic based on the vial's concentration and diluent volume, and it is separate from the question of what dose to use. The dosage calculator does the arithmetic for whatever amount you enter. It does not supply or endorse a dose.
When should I stop and get medical care?
Get emergency care (call 911 in the US) for signs of a severe allergic reaction: swelling of the face, lips, tongue or throat, or difficulty breathing. Do the same for any severe or rapidly worsening symptom, including lower-back pain, reduced urination or swelling, which can signal kidney involvement given this compound's renal-injury signal. Call Poison Control at 1-800-222-1222 for a suspected exposure to an unknown or excessive amount of anything sold as adipotide.
References (4 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Barnhart KF, Christianson DR, Hanley PW et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3(108):108ra112.StudyPMID 22072637full text
- 2.Fierce Biotech - Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide in a Phase 1 Clinical Trial. Source for the human trial's dose-escalation design described on this page.- Fierce Biotechother
- 3.ClinicalTrials.gov - registry entry for the MD Anderson-run, first-in-human Phase 1 trial of adipotide (prohibitin-targeting peptide 1) in men with metastatic prostate cancer and obesity. Search "prohibitin targeting peptide" on the site to find it directly. Confirms the trial status as terminated, per the principal investigator's request, with no dose or results posted.- ClinicalTrials.gov, US National Library of Medicinedatabase
- 4.America's Poison Centers - confirms 1-800-222-1222 as the national Poison Control number, free and confidential, 24 hours a day.- America's Poison Centersother